Curriculum Vitaes
Profile Information
- Affiliation
- Researcher, Joint Research Laboratory of Clinical Medicine, Fujita Health University
- Degree
- 博士(医学)(藤田保健衛生大学)
- ORCID ID
https://orcid.org/0000-0003-0110-5923- J-GLOBAL ID
- 202101003056000553
- researchmap Member ID
- R000029843
Research History
3Committee Memberships
6-
Jul, 2024 - Present
-
2022 - Present
-
2022 - Present
-
2020 - Present
-
2017 - Present
Papers
45-
Journal of atherosclerosis and thrombosis, 33(5) 566-577, May 1, 2026AIMS: The global distribution of lipoprotein(a) [Lp(a)] levels varies due to racial and ethnic differences. However, the clinical relevance of Lp(a) levels in Japanese patients has not been fully explored. METHODS: We investigated the association of Lp(a) levels, the Suita score, and the presence of high-risk plaque (HRP) as well as that of ≥ 50% stenosis, quantitative plaque volume, and the value of coronary artery calcium score in coronary computed tomographic angiography (CCTA), among 272 Japanese patients (mean age: 65 years) in whom serum Lp(a) levels were measured due to suspected coronary artery disease. HRP was defined as positive remodeling and/or low attenuation. Plaque volume was quantified as the percent plaque volume. RESULTS: HRP was identified in 33 (12.1%) patients. The prevalence of HRP, ≥ 50% stenosis, and percent plaque volume progressively increased with higher Lp (a) levels and Suita scores. In multivariate analyses, Lp(a) and the Suita score independently predicted HRP when assessed as continuous (p = 0.02, p<0.001, respectively) or categorical variables (p = 0.005, p = 0.007, respectively). Patients in the highest tertile of Lp(a) and classified as high- or intermediate-risk by the Suita score had the highest HRP risk, whereas those in the lower 2 tertiles and low-risk group had the lowest. Incorporating Lp(a) into the Suita score improved the prediction of HRP beyond the Suita score alone (p = 0.005). CONCLUSIONS: The combinatorial value of assessing Lp(a) levels and Suita score may provide useful insight regarding Japanese patients undergoing CCTA for the prediction of HRP.
-
日本臨床検査医学会誌, 73(補冊) 138-138, Jul, 2025
Misc.
28-
MEDICAL REHABILITATION, (262) 67-73, Jun, 2021
-
TRANSPLANT INTERNATIONAL, 26 51-51, Nov, 2013
-
NEPHROLOGY DIALYSIS TRANSPLANTATION, 27 109-110, May, 2012
-
CLINICAL CHEMISTRY, 55(6) A59-A60, Jun, 2009
-
CLINICAL CHEMISTRY, 55(6) A59-A59, Jun, 2009
-
CLINICAL CHEMISTRY, 55(6) A59-A59, Jun, 2009
-
CLINICAL CHEMISTRY, 55(6) A59-A59, Jun, 2009
-
CLINICAL CHEMISTRY, 54(6) A79-A79, Jun, 2008
-
CLINICAL CHEMISTRY, 54(6) A79-A79, Jun, 2008
-
CLINICAL CHEMISTRY, 54(6) A79-A79, Jun, 2008
-
CLINICAL CHEMISTRY, 53(6) A10-A10, Jun, 2007
-
CLINICAL CHEMISTRY, 53(6) A14-A14, Jun, 2007
-
Long-term prognostic value of cardiac troponin T in end-stage renal disease: 8-year outcome analysisCLINICAL CHEMISTRY, 53(6) A14-A14, Jun, 2007
-
藤田学園医学会誌, 30(2) 149-153, Dec, 2006住民検診受診者841例を対象に、心疾患スクリーニングにおけるN端末プロB型ナトリウム利尿ペプチド(NT-proBNP)濃度測定について検討した。NT-proBNP濃度の独立した規定因子は、年齢、性別、収縮期血圧、ヘモグロビン濃度、総コレステロール、クレアチニン・クリアランス、喫煙習慣、心血管疾患の既往(含:心電図異常)であった。また、NT-proBNPが基準値以上の81症例は、NT-proBNPが基準値以下の760症例に比べ、心疾患の既往(13例:16.0%)、心電図異常の頻度(31例:38.3%)、フラミンガムリスクスコアが有意に高値であった。NT-proBNP濃度の測定は、心疾患スクリーニングに有用である可能性が示唆された。
-
藤田学園医学会誌, 30(1) 7-10, Oct, 2006町民検診受診者841名を対象に、メタボリックシンドローム(MS)と血清アディポネクチン濃度との関係を検討した。MS診断基準には、本邦における、2005年4月に提示されたものを用いた。65例(7.7%)がMSと診断され(MS群)、男性は54例(17.6%)で、女性の11例(2.1%)より有意に高かった。喫煙者141例の血清アディポネクチン濃度は5.53μg/mlで、非喫煙者700例の8.20μg/mlより有意に低かった。対象841名を腹部肥満とMS危険因子数によって4群に分けた。血清アディポネクチン濃度は腹部肥満とMS危険因子数に関連し、非MS群(腹部肥満:なし、MS危険因子:〜1個)559名は7.72μg/ml、MS群(腹部肥満:あり、MS危険因子:2個)65名は3.31μg/mlであった。血清アディポネクチン濃度は腹部肥満、及び保有するMS危険因子の数に左右され、MSの診断に有用であることが示された。また、MSの診断だけでなく、性別、喫煙など生活習慣のリスクを総合的に反映するマーカーであると考えられた。
-
CLINICAL CHEMISTRY, 52(6) A132-A132, Jun, 2006
-
CLINICAL CHEMISTRY, 52(6) A132-A133, Jun, 2006
-
CLINICAL CHEMISTRY, 52(6) A132-A132, Jun, 2006
-
CLINICAL CHEMISTRY, 50(6) A2-A2, Jun, 2004
Presentations
21-
AACC annual meeting 2016 in Philadelphia
-
AACC annual meeting 2013 in Houston
Professional Memberships
9Research Projects
1-
科学研究費助成事業 基盤研究(C), 日本学術振興会, Apr, 2022 - Mar, 2025